研究方案:胶质母细胞瘤术前脑照射(POBIG)——一项Ⅰ期试验
POBIG是一项开放标签、双中心Ⅰ期剂量与体积递增试验,评估新诊断胶质母细胞瘤单次术前放疗的安全性和可行性,主要终点为最大耐受剂量(MTD)和最大耐受照射体积(MTIV)。术前放疗剂量6至14 Gy,随后行最大安全切除及术后替莫唑胺同步放化疗(60 Gy/30次)。
要点
- POBIG评估新诊断胶质母细胞瘤单次术前放疗(6–14 Gy)的MTD和MTIV。
- 剂量/体积递增由持续再评估方法(CRM)模型指导。
- 术前放疗靶区为术后残留风险最高的肿瘤区域(热点),部分肿瘤留作未照射(冷点)单独取样。
核心结论
- POBIG将帮助确立放疗在胶质母细胞瘤术前治疗模式中的作用。
研究设计与样本
- POBIG为开放标签、双中心Ⅰ期剂量与体积递增试验,已获伦理批准,注册号NCT03582514。
- 患者以新发胶质母细胞瘤影像学诊断进行筛选,因影像准确率高且为避免治疗延迟,此诊断即视为足够。
- 入组患者接受单次6至14 Gy术前放疗,随后行最大安全切除及术后放化疗(60 Gy/30次)联合同步及辅助替莫唑胺。
主要发现
- 原文未报告结果。
关键数值与推荐
- 主要终点为最大耐受剂量(MTD)和最大耐受照射体积(MTIV)。
- 术前放疗剂量范围为6至14 Gy,单次照射。
- 术后标准治疗为60 Gy/30次放疗联合同步及辅助替莫唑胺。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is a high-grade aggressive neoplasm whose outcomes have not changed in decades. In the current treatment pathway, tumour growth continues and remains untreated for several weeks post-diagnosis. Intensified upfront therapy could target otherwise untreated tumour cells and improve the treatment outcome. POBIG will evaluate the safety and feasibility of single-fraction preoperative radiotherapy for newly diagnosed glioblastoma, assessed by the maximum tolerated dose (MTD) and maximum tolerated irradiation volume (MTIV). METHODS: POBIG is an open-label, dual-centre phase I dose and volume escalation trial that has received ethical approval. Patients with a new radiological diagnosis of glioblastoma will be screened for eligibility. This is deemed sufficient due to the high accuracy of imaging and to avoid treatment delay. Eligible patients will receive a single fraction of preoperative radiotherapy ranging from 6 to 14 Gy followed by their standard of care treatment comprising maximal safe resection and postoperative chemoradiotherapy (60 Gy/30 fr) with concurrent and adjuvant temozolomide). Preoperative radiotherapy will be directed to the part of the tumour that is highest risk for remaining as postoperative residual disease (hot spot). Part of the tumour will remain unirradiated (cold spot) and sampled separately for diagnostic purposes. Dose/volume escalation will be guided by a Continual Reassessment Method (CRM) model. Translational opportunities will be afforded through comparison of irradiated and unirradiated primary glioblastoma tissue. DISCUSSION: POBIG will help establish the role of radiotherapy in preoperative modalities for glioblastoma. TRIAL REGISTRATION: NCT03582514 (clinicaltrials.gov).
引用
- Waqar M, Roncaroli F, Djoukhadar I, et al. Study protocol: PreOperative Brain Irradiation in Glioblastoma (POBIG) - A phase I trial. Clin Transl Radiat Oncol. 2023. PMID: 36845633. doi:10.1016/j.ctro.2023.100585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。